Studies from University Medical Center Mannheim Describe New Findings in Cutaneous T-Cell Lymphoma (Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma).

A study conducted at the University Medical Center Mannheim in Germany has found that a combination therapy of mogamulizumab and extracorporeal photopheresis (ECP) is an effective treatment for erythrodermic cutaneous T-cell lymphoma (CTCL). The study included 11 patients with CTCL who received this combination therapy, and it resulted in an overall response rate of 73% in the skin and 64% in the blood. The therapy was well-tolerated, with common adverse events including mogamulizumab-associated rash, anemia, lymphocytopenia, and infusion-related reactions. This research provides new treatment options for CTCL patients and highlights the importance of combination therapies in managing this rare lymphoproliferative malignancy. [Extracted from the article]